Mohamad Faisal Alibrahim

Dr. Mohamad Faisal Alibrahim


Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 January 2026 in Annals of Medicine & Surgery
Verified
Journal Article
Open access
AAAbd Alkarim Shams Aldeen
Abd Alkarim Shams Aldeen
RMRana Marta
Rana Marta
RTRitchelle Tannous
Ritchelle Tannous
TATark Abo Alaika
Tark Abo Alaika
MAMohamad Faisal Alibrahim
Mohamad Faisal Alibrahim
MSMouhammed Sleiay
Mouhammed Sleiay
Introduction and importance: Dextrocardia with situs solitus is an exceptionally rare congenital anomaly. Its asymptomatic nature may delay diagnosis, highlighting the need for careful prenatal and postnatal evaluation. Case Presentation: A full-term female neonate was found to have isolated dextrocardia with situs solitus following prenatal suspicion. Postnatal chest X-ray and echocardiography confirmed dextroversion with normal cardiac anatomy and function. No associated anomalies were found. The patient remained asymptomatic and was stable at 3-month follow-up. Clinical Discussion: Isolated dextrocardia with situs solitus is rare and often discovered incidentally. Our case illustrates the importance of thorough prenatal imaging and clinical follow-up to detect potential associated anomalies. Conclusion: Even when asymptomatic, dextrocardia requires comprehensive evaluation. This case contributes to the limited literature and emphasizes the value of imaging and vigilance in similar scenarios.

19 July 2026 in Discover Oncology
Verified
Journal Article
Open access
PDF file
ASAnas Shahin
Anas Shahin
MAMohamad Faisal Alibrahim
Mohamad Faisal Alibrahim
MKMohammad Ehsan Kawas
Mohammad Ehsan Kawas
REReham Elawi
Reham Elawi
Background: A persistent translational gap separates the high research-benchmark performance of artificial intelligence (AI) and advanced imaging in breast cancer from demonstrated real-world clinical utility. Most systems reporting accuracy above 95% on curated datasets have not been externally validated across diverse populations and imaging platforms. Purpose: We critically examine AI-driven diagnostics and advanced imaging modalities for breast cancer, focusing on the barriers—generalization failure, algorithmic bias, reproducibility, and workflow integration—that determine clinical readiness rather than on benchmark capability alone. Methods: We conducted a structured review of peer-reviewed literature (January 2015–March 2025) across PubMed, Scopus, IEEE Xplore, and Web of Science, combining breast cancer terms with AI, deep learning, vision transformers, digital breast tomosynthesis (DBT), contrast-enhanced mammography (CEM), MRI, and liquid biopsy. Study selection followed an explicit, PRISMA-style screening workflow; 127 of 312 identified records met predefined eligibility and quality criteria. Results: Reported benchmark performance is consistently optimistic relative to clinical performance: deep learning exceeds 95% accuracy and vision transformers report near-perfect classification on CBIS-DDSM, yet a reproducible 5–15% degradation follows deployment owing to distribution shift, scanner and vendor heterogeneity, and population differences. Among validated technologies, DBT raises cancer detection by 27% while lowering false positives; CEM increases sensitivity from 71.5% to 92.7% in dense breasts; and the Mirai risk model (AUC 0.76−0.81) outperforms traditional clinical tools. Liquid biopsy offers high-specificity molecular profiling but inadequate sensitivity (33%) for population screening. Critically, technical maturity is decoupled from validation depth and equity readiness—the dimensions that actually gate adoption. Conclusion: Realizing the potential of AI-augmented, risk-stratified screening requires multicenter prospective and multi-vendor external validation, fairness-aware design with subgroup reporting, transparent reproducibility, and adaptive regulation of continuously learning systems. We propose an operationally defined translational readiness framework that scores each technology along six dimensions, locating it on the continuum from research capability to equitable clinical deployment.